Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1540 • ACR Convergence 2024
Project HOPE: HydrOxychloroquine Adherence ProjEct
Meredith LiCalzi¹, Fotios Koumpouras² and Jacinta Renaldi³, ¹Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Yale New Haven Hospital, New Haven, CT
Background/Purpose: Hydroxychloroquine (HCQ) is known to reduce flares, improve disease activity and mortality in patients with systemic lupus erythematosus (SLE).1 Nonadherence to HCQ is a noteworthy…
Abstract Number: 1649 • ACR Convergence 2024
B Cell Subset Contribution to Autoantibodies in Lupus
Kristina Ottens¹, Jalyn Schneider¹ and Anne Satterthwaite², ¹UT Southwestern Medical Center, Dallas, ²UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Systemic lupus erythematous is characterized by the production of pathogenic autoantibodies that drive inflammation and tissue damage. Defining the B cell subsets that give…
Abstract Number: 1752 • ACR Convergence 2024
T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus
Jin Liu¹, Yuanxuan Xia¹, Dylan Ferris¹, Elana Shaw¹, Brian Mog¹, Alexander Pearlman¹, Brock Moritz¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Sarah DiNapoli¹, Tushar Nichakawade¹, Yang Li¹, Jiaxin Ge¹, Stephanie Glavaris¹, Nikita Marcou¹, Taha Ahmedna¹, Regina Bugrovsky², Scott A. Jenks², Chetan Bettegowda¹, Daniel Goldman³, Michelle Petri³, Iñaki Sanz⁴, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹, Suman Paul¹, Felipe Andrade⁵ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Emory University School of Medicine, Atlanta, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of…
Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Preetha Balasubramanian², Zurong Wan², Juan Rodriguez Alcazar², Marina Lima Silva Santos², Lynnette Walters³, Jeanine Baisch², Karen Onel⁴, Tracey Wright⁵, Virginia Pascual⁶ and Simone Caielli², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Scottish Rite Hospital for Children, Allen, TX, ⁴HSS, New York, NY, ⁵UT Southwestern, Plano, TX, ⁶Weill Cornell Medical College, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
Abstract Number: 1812 • ACR Convergence 2024
Glycosylation Changes as Non-Invasive Biomarkers for Lupus Nephritis Detection and Prognosis
Aaron Angerstein¹, Richard Drake², Vishwajeeth Pasham², Bethany Wolf², Jim Oates² and Tammy Nowling², ¹Medical University of South Carolina, North Charleston, SC, ²Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease predominantly affecting women of childbearing age. Roughly 50% of SLE patients develop Lupus Nephritis (LN),…
Abstract Number: 2026 • ACR Convergence 2024
Cardiovascular Risk Measured by PREVENT Calculator and Disease Activity in Patients with Systemic Lupus Erythematosus
Rebeca L. Polina-Lugo¹, Aleydis Gonzalez Melendez¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Annette Dominguez-Guerra³, Victoria P. Limas-Martínez¹, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: Increased disease activity by SLEDAI (Systemic Erythematosus Lupus Disease Activity Index) has been associated with higher cardiovascular risk (CVR) and atherosclerotic cardiovascular disease (ASCVD),…
Abstract Number: 2376 • ACR Convergence 2024
Systemic Lupus Erythematosus Patients Exhibit Dynamic Changes in Disease-Associated Transcripts Following Total Knee or Total Hip Arthroplasty
David Fernandez¹, Stephen Batter¹, Deanna Jannat-Khah¹, Mikhail Olferiev¹, Insa Mannstadt², Mark Figgie¹, Peter Sculco¹, Jason Blevins¹, Caroline Siegel¹, Dina Greenman¹, Kyriakos Kirou¹ and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University VP&S, New York, NY, ³Hospital for Special Surgery, New York 10025, NY
Background/Purpose: Patients with systemic lupus erythematosus (SLE) undergoing total hip arthroplasty and total knee arthroplasty (THA and TKA) experience higher complication rates than osteoarthritis (OA)…
Abstract Number: 2395 • ACR Convergence 2024
Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)
Antônio Silaide De Araújo-Júnior¹, Emília Sato², Alexandre Wagner Silva de Souza¹, Fábio Jennings¹, Gianna Mastroianni Kirsztajn³, Ricardo Sesso³ and Edgard Reis Neto⁴, ¹Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, ²Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, ³Division of Nephrology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil., São Paulo, SP, Brazil, ⁴Division of Rheumatology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal, São Paulo, SP, Brazil
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), and kidney biopsy is the gold…
Abstract Number: 2413 • ACR Convergence 2024
The Natural History of SLE Has Changed Since the 1970s
Adaobi Ugochukwu¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: We investigated the changes in the prevalence of specific SLE manifestations over the last 50 years. In addition, we looked for differences between African-Americans…
Abstract Number: 2429 • ACR Convergence 2024
Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
Carmen Raya-Santos¹, José Rosas-Gómez de Salazar², Mariana Marco³, Ana Pons-Bas³, Rocío Gallego Campuzano⁴, Juan Carlos Cortes⁴, Lara Pons-Canet³, Maruan Shalabi³, José Miguel Senabre³, José Antonio Bernal⁵, Gregorio Santos-Soler⁶, Xavier Barber⁷ and Jose Alberto Garcia Gomez⁷, ¹Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ³Hospital Marina Baixa, Villajoyosa, Spain, ⁴Hospital Marina Baixa, Villajoyosa, Comunidad Valenciana, Spain, ⁵Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ⁶Hospital Marina Baixa, Villajoyosa, ⁷Miguel Hernandez University, Villajoyosa, Spain
Background/Purpose: The administration of hydroxychloroquine-sulphate (HCQ) can lead to the risk of QTc prolongation and cardiac arrhythmias. We evaluated the HCQ concentration and the incidence…
Abstract Number: 2575 • ACR Convergence 2024
Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?
Paola Vidal¹, Javier Narvaez-García², Francesc-Xavier Fulladosa², Francesca Mitjavila², olga Capdevila², Pol Maymó³, Judith Palacios⁴ and Joan Miquel Nolla², ¹Hospital Universtiario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Bellvitge University Hospital, L'Hospitalet de Llobregat, Catalonia, Spain
Background/Purpose: The latest guidelines for managing lupus nephritis (LN), including the 2024 KDIGO guidelines and the 2019 EULAR/ERA-EDTA update, recommend a minimum immunosuppression (IS) duration…
Abstract Number: 2626 • ACR Convergence 2024
Identifying Homogeneous Endophenotypes in Childhood-Onset Systemic Lupus Erythematosus with Similarity Network Fusion
Nicholas C Chan¹, Nicholas Gold², Deborah Levy², Andrea Knight³, Earl Silverman⁴, Daniela Dominguez⁵, Lawrence Ng², Lauren Erdman² and Linda Hiraki², ¹University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Silverman, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Childhood-onset Systemic Lupus Erythematosus (cSLE) is a clinically heterogeneous autoimmune disease. We hypothesized that similarity network fusion (SNF) a data driven method would identify…
Abstract Number: 0004 • ACR Convergence 2024
Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Daniel Capon, Larisa Troitskaya, Marina Fomin, Brendon Frank, Ursula Edman, Benjamin Capon, Brian Law, Steven Chapin, Gavin Lewis, Malcolm Gefter, Juha Punnonen and Nelson Chan, Hinge Bio, Inc., Burlingame, CA
Background/Purpose: The dramatic demonstration of CD19 CAR-T efficacy in systemic lupus erythematosus (SLE), idiopathic inflammatory myositis, and systemic sclerosis by Georg Schett and colleagues (F.…
Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Jorge Armando Gonzalez-Chapa¹, Anders Bengtsson², Iva Gunnarsson³, Elisabet Svenungsson⁴ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Lund University, Lund, Sweden, ³Karolinska Institute, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…
Abstract Number: 0177 • ACR Convergence 2024
Rural-urban Disparities in the Myocardial Infarction Hospitalizations in People with Systemic Lupus Erythematosus in the US
Sumanth Chandrupatla¹ and Jasvinder Singh², ¹University of Alabama at Birmingham, Birmingham, AL, ²Baylor College of Medicine, Birmingham, AL
Background/Purpose: To assess whether rural-urban disparities exist in people with SLE for hospitalization with myocardial infarction (MI)Methods: We used the 2016-2019 U.S. National Inpatient Sample…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].